vs
ADMA BIOLOGICS, INC.（ADMA）与安进（AMGN）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是ADMA BIOLOGICS, INC.的70.9倍（$9.9B vs $139.2M）。ADMA BIOLOGICS, INC.净利率更高（35.5% vs 13.5%，领先22.0%）。ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 8.6%）。安进自由现金流更多（$961.0M vs $34.6M）。过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 15.1%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
ADMA vs AMGN — 直观对比
营收规模更大
AMGN
是对方的70.9倍
$139.2M
营收增速更快
ADMA
高出9.8%
8.6%
净利率更高
ADMA
高出22.0%
13.5%
自由现金流更多
AMGN
多$926.4M
$34.6M
两年增速更快
ADMA
近两年复合增速
15.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $9.9B |
| 净利润 | $49.4M | $1.3B |
| 毛利率 | 63.8% | 69.8% |
| 营业利润率 | 45.1% | 27.6% |
| 净利率 | 35.5% | 13.5% |
| 营收同比 | 18.4% | 8.6% |
| 净利润同比 | -55.9% | 112.6% |
| 每股收益（稀释后） | $0.20 | $2.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAAMGN
| Q4 25 | $139.2M | $9.9B | ||
| Q3 25 | $134.2M | $9.6B | ||
| Q2 25 | $122.0M | $9.2B | ||
| Q1 25 | $114.8M | $8.1B | ||
| Q4 24 | $117.5M | $9.1B | ||
| Q3 24 | $119.8M | $8.5B | ||
| Q2 24 | $107.2M | $8.4B | ||
| Q1 24 | $81.9M | $7.4B |
净利润ADMAAMGN
| Q4 25 | $49.4M | $1.3B | ||
| Q3 25 | $36.4M | $3.2B | ||
| Q2 25 | $34.2M | $1.4B | ||
| Q1 25 | $26.9M | $1.7B | ||
| Q4 24 | $111.9M | $627.0M | ||
| Q3 24 | $35.9M | $2.8B | ||
| Q2 24 | $32.1M | $746.0M | ||
| Q1 24 | $17.8M | $-113.0M |
毛利率ADMAAMGN
| Q4 25 | 63.8% | 69.8% | ||
| Q3 25 | 56.3% | 67.8% | ||
| Q2 25 | 55.1% | 67.2% | ||
| Q1 25 | 53.2% | 63.6% | ||
| Q4 24 | 53.9% | 65.7% | ||
| Q3 24 | 49.8% | 61.1% | ||
| Q2 24 | 53.6% | 61.4% | ||
| Q1 24 | 47.8% | 57.0% |
营业利润率ADMAAMGN
| Q4 25 | 45.1% | 27.6% | ||
| Q3 25 | 38.0% | 26.4% | ||
| Q2 25 | 35.1% | 28.9% | ||
| Q1 25 | 30.4% | 14.5% | ||
| Q4 24 | 32.6% | 25.4% | ||
| Q3 24 | 33.1% | 24.1% | ||
| Q2 24 | 36.6% | 22.8% | ||
| Q1 24 | 26.7% | 13.3% |
净利率ADMAAMGN
| Q4 25 | 35.5% | 13.5% | ||
| Q3 25 | 27.1% | 33.7% | ||
| Q2 25 | 28.1% | 15.6% | ||
| Q1 25 | 23.4% | 21.2% | ||
| Q4 24 | 95.2% | 6.9% | ||
| Q3 24 | 30.0% | 33.3% | ||
| Q2 24 | 29.9% | 8.9% | ||
| Q1 24 | 21.7% | -1.5% |
每股收益（稀释后）ADMAAMGN
| Q4 25 | $0.20 | $2.45 | ||
| Q3 25 | $0.15 | $5.93 | ||
| Q2 25 | $0.14 | $2.65 | ||
| Q1 25 | $0.11 | $3.20 | ||
| Q4 24 | $0.45 | $1.17 | ||
| Q3 24 | $0.15 | $5.22 | ||
| Q2 24 | $0.13 | $1.38 | ||
| Q1 24 | $0.08 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $9.1B |
| 总债务越低越好 | $72.1M | $54.6B |
| 股东权益账面价值 | $477.3M | $8.7B |
| 总资产 | $624.2M | $90.6B |
| 负债/权益比越低杠杆越低 | 0.15× | 6.31× |
8季度趋势，按日历期对齐
现金及短期投资ADMAAMGN
| Q4 25 | $87.6M | $9.1B | ||
| Q3 25 | $61.4M | $9.4B | ||
| Q2 25 | $90.3M | $8.0B | ||
| Q1 25 | $71.6M | $8.8B | ||
| Q4 24 | $103.1M | $12.0B | ||
| Q3 24 | $86.7M | $9.0B | ||
| Q2 24 | $88.2M | $9.3B | ||
| Q1 24 | $45.3M | $9.7B |
总债务ADMAAMGN
| Q4 25 | $72.1M | $54.6B | ||
| Q3 25 | $72.4M | $54.6B | ||
| Q2 25 | — | $56.2B | ||
| Q1 25 | — | $57.4B | ||
| Q4 24 | $72.3M | $60.1B | ||
| Q3 24 | — | $60.4B | ||
| Q2 24 | — | $62.6B | ||
| Q1 24 | — | $64.0B |
股东权益ADMAAMGN
| Q4 25 | $477.3M | $8.7B | ||
| Q3 25 | $431.2M | $9.6B | ||
| Q2 25 | $398.3M | $7.4B | ||
| Q1 25 | $373.4M | $6.2B | ||
| Q4 24 | $349.0M | $5.9B | ||
| Q3 24 | $231.9M | $7.5B | ||
| Q2 24 | $188.3M | $5.9B | ||
| Q1 24 | $153.7M | $5.0B |
总资产ADMAAMGN
| Q4 25 | $624.2M | $90.6B | ||
| Q3 25 | $568.7M | $90.1B | ||
| Q2 25 | $558.4M | $87.9B | ||
| Q1 25 | $510.6M | $89.4B | ||
| Q4 24 | $488.7M | $91.8B | ||
| Q3 24 | $390.6M | $90.9B | ||
| Q2 24 | $376.4M | $90.9B | ||
| Q1 24 | $350.9M | $93.0B |
负债/权益比ADMAAMGN
| Q4 25 | 0.15× | 6.31× | ||
| Q3 25 | 0.17× | 5.67× | ||
| Q2 25 | — | 7.57× | ||
| Q1 25 | — | 9.24× | ||
| Q4 24 | 0.21× | 10.23× | ||
| Q3 24 | — | 8.02× | ||
| Q2 24 | — | 10.57× | ||
| Q1 24 | — | 12.75× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $1.6B |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $961.0M |
| 自由现金流率自由现金流/营收 | 24.8% | 9.7% |
| 资本支出强度资本支出/营收 | 0.8% | 6.5% |
| 现金转化率经营现金流/净利润 | 0.72× | 1.20× |
| 过去12个月自由现金流最近4个季度 | $27.8M | $8.1B |
8季度趋势，按日历期对齐
经营现金流ADMAAMGN
| Q4 25 | $35.6M | $1.6B | ||
| Q3 25 | $13.3M | $4.7B | ||
| Q2 25 | $21.1M | $2.3B | ||
| Q1 25 | $-19.7M | $1.4B | ||
| Q4 24 | $50.2M | $4.8B | ||
| Q3 24 | $25.0M | $3.6B | ||
| Q2 24 | $45.6M | $2.5B | ||
| Q1 24 | $-2.2M | $689.0M |
自由现金流ADMAAMGN
| Q4 25 | $34.6M | $961.0M | ||
| Q3 25 | $-1.1M | $4.2B | ||
| Q2 25 | $18.7M | $1.9B | ||
| Q1 25 | $-24.4M | $980.0M | ||
| Q4 24 | $47.5M | $4.4B | ||
| Q3 24 | $24.0M | $3.3B | ||
| Q2 24 | $43.6M | $2.2B | ||
| Q1 24 | $-4.6M | $459.0M |
自由现金流率ADMAAMGN
| Q4 25 | 24.8% | 9.7% | ||
| Q3 25 | -0.8% | 44.4% | ||
| Q2 25 | 15.3% | 20.8% | ||
| Q1 25 | -21.2% | 12.0% | ||
| Q4 24 | 40.4% | 48.4% | ||
| Q3 24 | 20.0% | 39.0% | ||
| Q2 24 | 40.7% | 26.5% | ||
| Q1 24 | -5.6% | 6.2% |
资本支出强度ADMAAMGN
| Q4 25 | 0.8% | 6.5% | ||
| Q3 25 | 10.7% | 4.6% | ||
| Q2 25 | 2.0% | 4.0% | ||
| Q1 25 | 4.1% | 5.0% | ||
| Q4 24 | 2.3% | 4.1% | ||
| Q3 24 | 0.9% | 3.0% | ||
| Q2 24 | 1.9% | 2.8% | ||
| Q1 24 | 2.9% | 3.1% |
现金转化率ADMAAMGN
| Q4 25 | 0.72× | 1.20× | ||
| Q3 25 | 0.36× | 1.46× | ||
| Q2 25 | 0.62× | 1.59× | ||
| Q1 25 | -0.73× | 0.80× | ||
| Q4 24 | 0.45× | 7.61× | ||
| Q3 24 | 0.70× | 1.26× | ||
| Q2 24 | 1.42× | 3.30× | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
暂无分部数据
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
